A Mid-Sized Diagnostics Company Decides it Can't do Everything
Executive SummaryThe rapid consolidation in diagnostics doesn't leave room for mid-sized players like Chiron Corp., which has been looking for a strategic partner for its diagnostics subsidiary for some time. Chiron Diagnostics needs to expand the breadth of its product line, according to an executive at the company.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.